Dr Roux is a Consultant Medical Oncologist with specialist expertise in the management of gynaecological and breast cancers. Her clinical practice is closely integrated with research, with a strong focus on the use of novel and targeted therapies alongside standard treatments, and active involvement in clinical trials to improve patient outcomes, and support for patients in the management of medical and surgical menopause.

• Advanced ovarian and endometrial cancer
• Use of targeted treatments in combination with chemotherapy
• Novel agents, including PARP inhibitors, anti-angiogenics and immunotherapy
• Early and advanced breast cancer
• Chemotherapy and biological therapies
• Targeted agents, including CDK4/6 inhibitors, ADCs, novel SERDs
• Immunotherapy
• Clinical trial involvement
• Management of medical and surgical menopause

Menopause support during cancer treatment

Dr Roux provides personalised support for patients experiencing medical or surgical menopause. As medically or surgically induced menopause leads to sudden hormone loss, it may cause more severe symptoms than natural menopause. Dr Roux actively helps patients understand and manage these symptoms alongside their cancer treatment.

Support includes:

• Medical menopause – Support for patients whose menopause is caused by cancer treatments, such as chemotherapy and hormone therapies.
• Surgical menopause – Guidance and support for patients who experience menopause after the removal of the ovaries.
• Managing treatment side effects – Guidance on managing symptoms such as night sweats, hot flushes, sleep difficulties, and other menopause-related side effects that may affect quality of life.
• Supportive care – Individualised support and strategies for management of the physical and emotional effects of menopause during and after cancer treatment, as part of their personalised holistic cancer care.

I take a personalised, evidence-based approach to cancer care, combining the most effective standard treatments with access to innovative therapies and clinical trials, and I strive to support each patient with clarity, compassion, and the best possible outcomes throughout their journey. Dr Rene Roux

• Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK - PubMed
• Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer - PubMed
• Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial - PubMed
• Roux R - Search Results - PubMed

• Derek Butler fellowship award during research at the ICR
• Finalist in Patients Choice Award at OUH

GMC reference number: 4486280